{"count": 5, "results": [{"_id": "33531904", "pmid": 33531904, "pmcid": "PMC7834834", "title": "Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?", "journal": "Adv Hematol", "authors": ["da Cunha Júnior AD", "Zanette DL", "Pericole FV", "Olalla Saad ST", "Barreto Campello Carvalheira J"], "date": "2021-01-18T00:00:00Z", "doi": "10.1155/2021/6615684", "meta_date_publication": "2021", "meta_volume": "2021", "meta_issue": "", "meta_pages": "6615684", "score": 50294.35, "text_hl": "Consistent with this interconnection, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ could predominantly exert inhibition of these pathophysiological factors and thus be an attractive therapeutic option for @<m>DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance</m> @DISEASE_MESH:D008998 @@@MGUS@@@. ", "citations": {"NLM": "da Cunha Júnior AD, Zanette DL, Pericole FV, Olalla Saad ST, Barreto Campello Carvalheira J. Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment? Adv Hematol. 2021;2021():6615684. PMID: 33531904", "BibTeX": "@article{33531904, title={Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?}, author={da Cunha Júnior AD and Zanette DL and Pericole FV and Olalla Saad ST and Barreto Campello Carvalheira J}, journal={Adv Hematol}, volume={2021}, pages={6615684}}"}}, {"_id": "37364455", "pmid": 37364455, "title": "Repurposing Metformin in hematologic tumor: State of art.", "journal": "Curr Probl Cancer", "authors": ["Hu M", "Chen Y", "Ma T", "Jing L"], "date": "2023-06-20T00:00:00Z", "doi": "10.1016/j.currproblcancer.2023.100972", "meta_date_publication": "2023 Jun 20", "meta_volume": "47", "meta_issue": "4", "meta_pages": "100972", "score": 50269.355, "text_hl": "The combination of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and chemotherapy enhances the efficacy of chemotherapy, and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ reduces the progression of @<m>DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance</m> @DISEASE_MESH:D008998 @@@monoclonal gammopathy of undetermined significance@@@ (@<m>DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance</m> @DISEASE_MESH:D008998 @@@MGUS@@@) to @DISEASE_Multiple_Myeloma @DISEASE_MESH:D009101 @@@MM@@@. ", "citations": {"NLM": "Hu M, Chen Y, Ma T, Jing L. Repurposing Metformin in hematologic tumor: State of art. Curr Probl Cancer. 2023 Jun 20;47(4):100972. PMID: 37364455", "BibTeX": "@article{37364455, title={Repurposing Metformin in hematologic tumor: State of art.}, author={Hu M and Chen Y and Ma T and Jing L}, journal={Curr Probl Cancer}, volume={47}, number={4}, pages={100972}}"}}, {"_id": "35344184", "pmid": 35344184, "title": "Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?", "journal": "Adv Ther", "authors": ["Papachristou S", "Popovic DS", "Papanas N"], "date": "2022-06-01T00:00:00Z", "doi": "10.1007/s12325-022-02125-1", "meta_date_publication": "2022 Jun", "meta_volume": "39", "meta_issue": "6", "meta_pages": "2283-2286", "score": 50265.773, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ studies dedicated to @<m>DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance</m> @DISEASE_MESH:D008998 @@@MGUS@@@ are currently very limited, yet it would appear that there may be hope for reducing progression of @<m>DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance</m> @DISEASE_MESH:D008998 @@@MGUS@@@ to @DISEASE_Multiple_Myeloma @DISEASE_MESH:D009101 @@@multiple myeloma@@@ with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@. ", "citations": {"NLM": "Papachristou S, Popovic DS, Papanas N. Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises? Adv Ther. 2022 Jun;39(6):2283-2286. PMID: 35344184", "BibTeX": "@article{35344184, title={Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?}, author={Papachristou S and Popovic DS and Papanas N}, journal={Adv Ther}, volume={39}, number={6}, pages={2283-2286}}"}}, {"_id": "26953904", "pmid": 26953904, "title": "Reappraisal of risk factors for monoclonal gammopathy of undetermined significance.", "journal": "Am J Hematol", "authors": ["Boursi B", "Weiss BM", "Haynes K", "Mamtani R", "Yang YX"], "date": "2016-06-01T00:00:00Z", "doi": "10.1002/ajh.24355", "meta_date_publication": "2016 Jun", "meta_volume": "91", "meta_issue": "6", "meta_pages": "581-4", "score": 50075.715, "text_hl": "In summary, while previously described risk factors for @<m>DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance</m> @DISEASE_MESH:D008998 @@@MGUS@@@ might be the result of detection bias, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ should be further evaluated as a possible chemoprevention modality. ", "citations": {"NLM": "Boursi B, Weiss BM, Haynes K, Mamtani R, Yang YX. Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. Am J Hematol. 2016 Jun;91(6):581-4. PMID: 26953904", "BibTeX": "@article{26953904, title={Reappraisal of risk factors for monoclonal gammopathy of undetermined significance.}, author={Boursi B and Weiss BM and Haynes K and Mamtani R and Yang YX}, journal={Am J Hematol}, volume={91}, number={6}, pages={581-4}}"}}, {"_id": "26034780", "pmid": 26034780, "title": "Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.", "journal": "Lancet Haematol", "authors": ["Chang SH", "Luo S", "O'Brian KK", "Thomas TS", "Colditz GA", "Carlsson NP", "Carson KR"], "date": "2015-01-01T00:00:00Z", "doi": "10.1016/S2352-3026(14)00037-4", "meta_date_publication": "2015 Jan", "meta_volume": "2", "meta_issue": "1", "meta_pages": "e30-6", "score": 50067.27, "text_hl": "We used Kaplan-Meier curves and Cox models to analyse the association between @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use and @<m>DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance</m> @DISEASE_MESH:D008998 @@@MGUS@@@ progression. ", "citations": {"NLM": "Chang SH, Luo S, O'Brian KK, Thomas TS, Colditz GA, Carlsson NP, Carson KR. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. Lancet Haematol. 2015 Jan;2(1):e30-6. PMID: 26034780", "BibTeX": "@article{26034780, title={Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.}, author={Chang SH and Luo S and O'Brian KK and Thomas TS and Colditz GA and Carlsson NP and Carson KR}, journal={Lancet Haematol}, volume={2}, number={1}, pages={e30-6}}"}}]}